94 related articles for article (PubMed ID: 26087525)
1. On the horizon: better bone-building drugs?
Mayo Clin Health Lett; 2014 Dec; 32(12):4. PubMed ID: 26087525
[No Abstract] [Full Text] [Related]
2. Merck &Co. drops osteoporosis drug odanacatib.
Mullard A
Nat Rev Drug Discov; 2016 Sep; 15(10):669. PubMed ID: 27681784
[No Abstract] [Full Text] [Related]
3. From Bone Cell Biology to Novel Therapies of Osteoporosis.
Hofbauer LC
Drug Res (Stuttg); 2015 Nov; 65 Suppl 1():S14-5. PubMed ID: 26536179
[No Abstract] [Full Text] [Related]
4. Two pioneering osteoporosis drugs finally approach approval.
Garber K
Nat Rev Drug Discov; 2016 Jun; 15(7):445-6. PubMed ID: 27357010
[No Abstract] [Full Text] [Related]
5. The biphenyl-carboxylate derivative ABD328 is a novel orally active antiresorptive agent.
Idris AI; Coste E; Greig IR; Ralston SH; van't Hof RJ
Calcif Tissue Int; 2010 Dec; 87(6):525-32. PubMed ID: 20852852
[TBL] [Abstract][Full Text] [Related]
6. [Drug treatment of osteoporosis].
Fassbender WJ; Willmann B
Dtsch Med Wochenschr; 2014 Mar; 139(10):497-500. PubMed ID: 24570199
[No Abstract] [Full Text] [Related]
7. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
Shiraki M
Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147
[No Abstract] [Full Text] [Related]
8. New therapeutic targets and agents for osteoporosis.
Rozenberg S
Maturitas; 2010 Apr; 65(4):299-300. PubMed ID: 20172667
[No Abstract] [Full Text] [Related]
9. [New bone density conservation agents for osteoporosis under research and development: ED-71].
Hagino H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():454-8. PubMed ID: 18161148
[No Abstract] [Full Text] [Related]
10. [Bone remodeling: new therapeutic approaches].
Ferrari S
Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for osteoporosis--where do we go from here?
Whitaker M; Guo J; Kehoe T; Benson G
N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168
[No Abstract] [Full Text] [Related]
12. Update on therapy for osteoporosis.
Licata AA
Orthop Nurs; 2007; 26(3):162-6; quiz 167-8. PubMed ID: 17538470
[TBL] [Abstract][Full Text] [Related]
13. [Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
Yamada S; Inaba M; Nishizawa Y
Nihon Rinsho; 2007 Nov; 65 Suppl 9():348-51. PubMed ID: 18161129
[No Abstract] [Full Text] [Related]
14. Bisphosphonates in the treatment of osteoporosis.
Poole KE; Compston JE
BMJ; 2012 May; 344():e3211. PubMed ID: 22619192
[No Abstract] [Full Text] [Related]
15. New therapeutics for osteoporosis.
Ng KW; Martin TJ
Curr Opin Pharmacol; 2014 Jun; 16():58-63. PubMed ID: 24699340
[TBL] [Abstract][Full Text] [Related]
16. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
Voskaridou E; Christoulas D; Antoniadou L; Terpos E
Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
[No Abstract] [Full Text] [Related]
17. [When should bisphosphonate treatment be discontinued?].
Eriksen EF; Halse J
Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
[No Abstract] [Full Text] [Related]
18. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
Marumo K; Saito M
Nihon Rinsho; 2011 Jul; 69(7):1264-9. PubMed ID: 21774369
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K2: a novel therapy for osteoporosis.
Prabhoo R; Prabhoo TR
J Indian Med Assoc; 2010 Apr; 108(4):253-4, 256-8. PubMed ID: 21114195
[TBL] [Abstract][Full Text] [Related]
20. Strontium ranelate and risk of vertebral fractures in frail osteoporotic women.
Rolland Y; Abellan Van Kan G; Gillette-Guyonnet S; Roux C; Boonen S; Vellas B
Bone; 2011 Feb; 48(2):332-8. PubMed ID: 20817053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
